As COVID-19 continues to change the clinical trial landscape, innovations in site and patient engagements will help determine the success of oncology trials.
Join us for our upcoming webinar with Dr. Ari VanderWalde, a member of George Clinical’s scientific leadership team with oncology clinical research expertise, May 27th.
This webcast will give the oncology community an in-depth understanding of preparing safe and efficient trials and implementing best practices to mitigate disruption during COVID-19 restrictions.
Topics covered in this webinar include:
The session will be streamed live on: May 27, 11:00 am USA CDT
Dr. Ari VanderWalde is an internationally recognized researcher providing expertise in oncology clinical trials with a focus on immune therapies in solid tumors and melanoma. He has worked in the pharmaceutical industry helping lead the approval of a new compound in Melanoma. Along with this experience, he also works at a premier cancer research institute and as a scientific expert in a global CRO specializing in oncology.
In addition, Dr. VanderWalde has collaborated and participated on advisory boards with many of the nation’s thought leaders and top experts in the field and holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology. He is involved in research that can improve treatment for cancer patients by targeting therapy in a more personalized fashion based on immune markers and aberrations in cancer genetics.
Meet with George Clinical! Contact us to schedule a time now.